Biologic therapies in ulcerative colitis: primi inter pares?

E-ISSN： 1873-5592|19|7|748-756

ISSN： 1389-4501

Source： Current Drug Targets, Vol.19, Iss.7, 2018-04, pp. : 748-756

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunosuppressive and biologic therapy for ulcerative colitis

By Ardizzone Sandro Cassinotti Andrea de Franchis Roberto

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 4, 2012-12 ,pp. : 449-467

Informa Healthcare

Access to resources Recommend Favorite

Comparative Tolerability of Therapies for Ulcerative Colitis

By Ardizzone S. Porro G.B.

Drug Safety, Vol. 25, Iss. 8, 2002-01 ,pp. : 561-582

Adis International

Access to resources Recommend Favorite

Novel therapies in the treatment of ulcerative colitis

By Tuvlin Jeffrey A Kane Sunanda V

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 3, 2003-03 ,pp. : 483-490

Informa Healthcare

Access to resources Recommend Favorite

Novel therapies in the treatment of ulcerative colitis

By Kane Sunanda V

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 7, 2001-07 ,pp. : 1223-1229

Informa Healthcare

Access to resources Recommend Favorite

Investigational cytokine-targeted therapies for ulcerative colitis

By Monteleone Giovanni

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 9, 2013-09 ,pp. : 1123-1132

Informa Healthcare

Access to resources Recommend Favorite